CIBC Bancorp USA
BCRX icon

CIBC Bancorp USA’s BioCryst Pharmaceuticals BCRX Stock Holding History

CIBC Bancorp USA’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$185K Buy
22,259
+9,376
+73% +$88.3K ﹤0.01% 2007
2026
Q2 		$129K Buy
12,883
+1,485
+13% +$13.4K ﹤0.01% 1833
2026
Q1 		$109K Buy
+11,398
New +$88.5K ﹤0.01% 1674
2025
Q3 		$169K Buy
+22,330
New +$186K ﹤0.01% 1301

Other funds holding BCRX

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
JHC
Jones Hill Capital New York $589M AUM
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Jupiter Asset Management
Jupiter Asset Management London, United Kingdom $21.4B AUM 19.74% 1-Year Est. Return

CIBC Bancorp USA's BCRX Position: Q3 2026 in Review

CIBC Bancorp USA increased its BioCryst Pharmaceuticals (BCRX) stake by 73% in Q3 2026, buying an estimated $88.3K and bringing the position to 22,259 shares worth $185K. The position accounts for ﹤0.01% of the portfolio, ranked #2007.

CIBC Bancorp USA first reported a position in BCRX in Q3 2025 and has held it in 4 quarters since. 241 funds tracked by Wall St. Rank hold BCRX as of Q3 2026.

  • CIBC Bancorp USA held 22,259 shares of BioCryst Pharmaceuticals worth $185K as of Q3 2026.
  • CIBC Bancorp USA bought 9,376 BioCryst Pharmaceuticals shares in Q3 2026, an estimated $88.3K.
  • BioCryst Pharmaceuticals made up ﹤0.01% of CIBC Bancorp USA's portfolio in Q3 2026, its #2007 holding.
  • CIBC Bancorp USA first reported a position in BioCryst Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • 241 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2026.

Based on CIBC Bancorp USA's 13F filing for Q3 2026, filed 13 Nov 2026.